US6584357B1
(en)
*
|
2000-10-17 |
2003-06-24 |
Sony Corporation |
Method and system for forming an acoustic signal from neural timing difference data
|
SK7822003A3
(en)
*
|
2000-12-21 |
2003-12-02 |
Aventis Pharma Gmbh |
Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
|
DE60221798T2
(de)
*
|
2001-01-26 |
2008-06-05 |
Schering Corp. |
Kombinationen von gallensäure sequestriermitteln und hemmern der sterol absorption zur behandlung von kardiovaskulären indikationen
|
CN100509058C
(zh)
*
|
2001-01-26 |
2009-07-08 |
先灵公司 |
过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药以及对于血管适应症的治疗
|
EP1353695A2
(en)
*
|
2001-01-26 |
2003-10-22 |
Schering Corporation |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
|
AR032643A1
(es)
*
|
2001-01-26 |
2003-11-19 |
Schering Corp |
Combinaciones de inhibidor(es) de absorcion de esterol con agente(s) cardiovascular(es) para el tratamiento de condiciones vasculares
|
SK9502003A3
(en)
*
|
2001-01-26 |
2003-12-02 |
Schering Corp |
Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
|
NZ527852A
(en)
|
2001-03-28 |
2005-03-24 |
Schering Corp |
Enantioselective synthesis of azetidinone intermediate compounds
|
US7056906B2
(en)
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
ES2272776T3
(es)
*
|
2001-09-21 |
2007-05-01 |
Schering Corporation |
Tratamiento de xantomas con derivados de azetidinona como inhibidores de la absorcion de esterol.
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
US20030204096A1
(en)
*
|
2002-03-25 |
2003-10-30 |
Schering Corporation |
Enantioselective synthesis of azetidinone intermediate compounds
|
US7176193B2
(en)
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
US7671047B2
(en)
|
2002-06-19 |
2010-03-02 |
Sanofi-Aventis Deutschland Gmbh |
Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
DE10227508A1
(de)
*
|
2002-06-19 |
2004-01-08 |
Aventis Pharma Deutschland Gmbh |
Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
US7176194B2
(en)
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
DE10227507A1
(de)
*
|
2002-06-19 |
2004-01-08 |
Aventis Pharma Deutschland Gmbh |
Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
GB0215579D0
(en)
*
|
2002-07-05 |
2002-08-14 |
Astrazeneca Ab |
Chemical compounds
|
DE10308353A1
(de)
|
2003-02-27 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
US7148246B2
(en)
|
2003-02-27 |
2006-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
|
DE10308351A1
(de)
|
2003-02-27 |
2004-11-25 |
Aventis Pharma Deutschland Gmbh |
1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10308355A1
(de)
|
2003-02-27 |
2004-12-23 |
Aventis Pharma Deutschland Gmbh |
Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
DE10308352A1
(de)
|
2003-02-27 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
MXPA05009503A
(es)
|
2003-03-07 |
2005-10-18 |
Schering Corp |
Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
|
US7459442B2
(en)
*
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
MXPA05009501A
(es)
|
2003-03-07 |
2005-10-18 |
Schering Corp |
Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
|
DE10314610A1
(de)
*
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
JP2007509963A
(ja)
*
|
2003-10-30 |
2007-04-19 |
メルク エンド カムパニー インコーポレーテッド |
抗高コレステロール血漿薬としての2−アゼチジノン
|
EP1918000A2
(en)
|
2003-11-05 |
2008-05-07 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
PL1682499T3
(pl)
*
|
2003-11-10 |
2008-01-31 |
Microbia Inc |
4-Biarylilo-1-fenyloazetydyn-2-ony
|
SI1682499T1
(sl)
*
|
2003-11-10 |
2008-02-29 |
Microbia Inc |
4-biarilil-1-fenilazetidin-2-oni
|
BRPI0416639A
(pt)
|
2003-11-19 |
2007-01-16 |
Metabasis Therapeutics Inc |
tiromiméticos contendo fósforo
|
JP4688819B2
(ja)
|
2003-12-23 |
2011-05-25 |
アストラゼネカ アクチボラグ |
コレステロール吸収阻害活性を有するジフェニルアゼチジノン誘導体
|
CN100471835C
(zh)
*
|
2003-12-23 |
2009-03-25 |
默克公司 |
抗高胆固醇血症化合物
|
US7241787B2
(en)
|
2004-01-25 |
2007-07-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
|
EP1586573B1
(en)
|
2004-04-01 |
2007-02-07 |
Sanofi-Aventis Deutschland GmbH |
Oxadiazolones, processes for their preparation and their use as pharmaceuticals
|
BRPI0510150A
(pt)
*
|
2004-05-21 |
2007-10-02 |
Sanofi Aventis Deutschland |
processo para preparação de derivados de 1,4-difenilacetidinonas
|
DOP2005000123A
(es)
*
|
2004-07-02 |
2011-07-15 |
Merck Sharp & Dohme |
Inhibidores de cetp
|
CA2581596A1
(en)
*
|
2004-09-29 |
2006-04-13 |
Schering Corporation |
Combinations of substituted azetidonones and cb1 antagonists
|
ES2435790T3
(es)
|
2004-12-03 |
2013-12-23 |
Intervet International B.V. |
Piperazinas sustituidas como antagonistas de CB1
|
US20060135755A1
(en)
|
2004-12-20 |
2006-06-22 |
Schering Corporation |
Process for the synthesis of azetidinones
|
TW200726746A
(en)
*
|
2005-05-06 |
2007-07-16 |
Microbia Inc |
Processes for production of 4-biphenylylazetidin-2-ones
|
EA200702464A1
(ru)
*
|
2005-05-11 |
2008-04-28 |
Майкробиа, Инк. |
Способы получения фенольных 4-бифенилилазетидин-2-онов
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
BRPI0611415A2
(pt)
*
|
2005-05-25 |
2010-09-08 |
Microbia Inc |
ácidos fosfÈnicos de 4-(bifenilil)azetidin-2-ona e processo para a produção dos mesmos
|
DE102005026762A1
(de)
|
2005-06-09 |
2006-12-21 |
Sanofi-Aventis Deutschland Gmbh |
Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
|
JP2008543837A
(ja)
*
|
2005-06-15 |
2008-12-04 |
メルク エンド カムパニー インコーポレーテッド |
抗高コレステロール血症化合物
|
WO2007001975A1
(en)
*
|
2005-06-20 |
2007-01-04 |
Schering Corporation |
Piperidine derivatives useful as histamine h3 antagonists
|
SA06270191B1
(ar)
|
2005-06-22 |
2010-03-29 |
استرازينيكا ايه بي |
مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
|
TW200806623A
(en)
*
|
2005-10-05 |
2008-02-01 |
Merck & Co Inc |
Anti-hypercholesterolemic compounds
|
WO2007075702A2
(en)
*
|
2005-12-21 |
2007-07-05 |
Schering Corporation |
Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
|
AR059021A1
(es)
*
|
2006-01-18 |
2008-03-05 |
Schering Corp |
Moduladores de receptores cannabinoides
|
AR060623A1
(es)
|
2006-04-27 |
2008-07-02 |
Astrazeneca Ab |
Compuestos derivados de 2-azetidinona y un metodo de preparacion
|
EP2061767B1
(de)
|
2006-08-08 |
2014-12-17 |
Sanofi |
Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
|
MX2009002398A
(es)
*
|
2006-09-05 |
2009-03-16 |
Schering Corp |
Combinaciones farmaceuticas para manejo de lipidos y en el tratamiento de aterosclerosis y estatosis hepatica.
|
KR20090071589A
(ko)
|
2006-09-15 |
2009-07-01 |
쉐링 코포레이션 |
통증 및 지질 대사 장애의 치료에 유용한 아제티딘 및 아제티돈 유도체
|
MX2009002924A
(es)
*
|
2006-09-15 |
2009-05-28 |
Schering Corp |
Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos.
|
US7638526B2
(en)
*
|
2006-09-15 |
2009-12-29 |
Schering Corporation |
Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
|
CN101583612A
(zh)
*
|
2006-09-15 |
2009-11-18 |
先灵公司 |
治疗脂质代谢障碍的氮杂环丁酮衍生物
|
AU2007318058A1
(en)
*
|
2006-11-02 |
2008-05-15 |
Merck Sharp & Dohme Corp. |
Heterocyclyl-substituted anti-hypercholesterolemic compounds
|
WO2008130616A2
(en)
*
|
2007-04-19 |
2008-10-30 |
Schering Corporation |
Diaryl morpholines as cb1 modulators
|
DE102007029612A1
(de)
|
2007-06-27 |
2009-01-08 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung von Pentahydroxyhexylcarbamoylundekan- säurebenzylester
|
US20080319221A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
US20080319218A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Andreas Haubrich |
Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
|
MX2010000334A
(es)
*
|
2007-06-28 |
2010-04-22 |
Intervet Int Bv |
Piperazinas sustituidas como antagonistas de cannabinoides 1.
|
WO2009005671A2
(en)
*
|
2007-06-28 |
2009-01-08 |
Schering Corporation |
Substituted piperazines as cb1 antagonists
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE102007054497B3
(de)
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
EP2242745A1
(de)
*
|
2008-02-07 |
2010-10-27 |
Sanofi-Aventis |
Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2370399A4
(en)
|
2008-12-11 |
2013-05-22 |
Agency Science Tech & Res |
GLUCOSE-PEG CONJUGATES TO REDUCE TRANSPORT OF GLUCOSE IN A CELL
|
US20110243940A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Bicyclic pyranone derivatives and methods of use thereof
|
US20110245209A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Pyridopyrimidine derivatives and methods of use thereof
|
WO2010093601A1
(en)
|
2009-02-10 |
2010-08-19 |
Metabasis Therapeutics, Inc. |
Novel sulfonic acid-containing thyromimetics, and methods for their use
|
WO2010100255A1
(en)
|
2009-03-06 |
2010-09-10 |
Lipideon Biotechnology Ag |
Pharmaceutical hypocholesterolemic compositions
|
WO2010113175A2
(en)
|
2009-04-01 |
2010-10-07 |
Matrix Laboratories Ltd |
Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
|
CN101993403B
(zh)
|
2009-08-11 |
2012-07-11 |
浙江海正药业股份有限公司 |
氮杂环丁酮类化合物及医药应用
|
DE102010015123A1
(de)
|
2010-04-16 |
2011-10-20 |
Sanofi-Aventis Deutschland Gmbh |
Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
WO2011140219A1
(en)
|
2010-05-04 |
2011-11-10 |
Codexis, Inc. |
Biocatalysts for ezetimibe synthesis
|
EP3593802A3
(en)
|
2010-05-26 |
2020-03-25 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
|
WO2011157827A1
(de)
|
2010-06-18 |
2011-12-22 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
ES2372460B1
(es)
*
|
2010-07-09 |
2012-11-16 |
Moehs Ibérica S.L. |
Nuevo método para la preparación de ezetimiba.
|
EP2683700B1
(de)
|
2011-03-08 |
2015-02-18 |
Sanofi |
Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US8846666B2
(en)
|
2011-03-08 |
2014-09-30 |
Sanofi |
Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
EP2683702B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2683705B1
(de)
|
2011-03-08 |
2015-04-22 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
EP2683698B1
(de)
|
2011-03-08 |
2017-10-04 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8710050B2
(en)
|
2011-03-08 |
2014-04-29 |
Sanofi |
Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
WO2012120052A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2683703B1
(de)
|
2011-03-08 |
2015-05-27 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
WO2012120053A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
CN102219803B
(zh)
*
|
2011-04-20 |
2013-07-31 |
浙江大学 |
一种伊替米贝中间体的制备方法
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
SG10201406155QA
(en)
|
2011-10-28 |
2014-11-27 |
Lumena Pharmaceuticals Inc |
Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
|
US20140243281A1
(en)
|
2011-10-28 |
2014-08-28 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
|
CN102746249B
(zh)
*
|
2012-07-07 |
2013-12-25 |
山东诚创医药技术开发有限公司 |
一种依折麦布中间体的纯化精制方法
|
JP2016514684A
(ja)
|
2013-03-15 |
2016-05-23 |
ルメナ ファーマシューティカルズ エルエルシー |
原発性硬化性胆管炎および炎症性腸疾患の処置のための胆汁酸再循環阻害剤
|
AU2014229050A1
(en)
|
2013-03-15 |
2015-10-22 |
Lumena Pharmaceuticals Llc |
Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
|
CN104513187B
(zh)
*
|
2015-01-09 |
2017-05-31 |
安润医药科技(苏州)有限公司 |
依折麦布及其中间体的合成方法
|
MX2021009625A
(es)
|
2019-02-12 |
2021-11-04 |
Mirum Pharmaceuticals Inc |
Métodos para incrementar el crecimiento en sujetos pediátricos que tienen enfermedad de hígado colestásico.
|
EP3942048A1
(en)
|
2019-03-20 |
2022-01-26 |
Regeneron Pharmaceuticals, Inc. |
Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (srebf1) inhibitors
|
CA3133002A1
(en)
|
2019-03-20 |
2020-09-24 |
Regeneron Pharmaceuticals, Inc. |
Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors
|